Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Pathologic Complete Response × relugolix × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3 Pathologic Complete Response 1 Neoplasm, Residual 1 Metastatic Castration-Resistant Prostate Cancer 1 Endometriosis 1 Adenocarcinoma 1

Interventions

thymoglobulin 1 relugolix 1 fludarabine phosphate 1 fludarabine 1 enzalutamide 1 Whole-Body Irradiation 1 Tacrolimus 1 Surgical Procedures, Operative 1 Rituximab 1 Observation 1 Mycophenolic Acid 1 Melphalan 1 Clofarabine 1 Busulfan 1 Bone Marrow Transplantation 1 Blood Specimen Collection 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

University of Oklahoma

Phase 1 Recruiting

Pathologic Complete Response, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡